GLP-1 Analog Liraglutide Enhances Proinsulin Processing in Pancreatic β-Cells via a PKA-Dependent Pathway
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Hyperproinsulinemia has gained increasing attention in the development of type 2 diabetes. Clinical studies have demonstrated that glucagon-like peptide-1 (GLP-1)-based therapies significantly decrease plasma proinsulin/insulin ratio in patients with type 2 diabetes. However, the underlying mechanism remains unclear. Prohormone convertase (PC)-1/3 and PC2 are primarily responsible for processing proinsulin to insulin in pancreatic β-cells. We have recently reported that Pax6 mutation down-regulated PC1/3 and PC2 expression, resulting in defective proinsulin processing in Pax6 heterozygous mutant (Pax6m/+) mice. In this study, we investigated whether and how liraglutide, a novel GLP-1 analog, modulated proinsulin processing. Our results showed that liraglutide significantly up-regulated PC1/3 expression and decreased the proinsulin to insulin ratio in both Pax6m/+ and db/db diabetic mice. In the cultured mouse pancreatic β-cell line, Min6, liraglutide stimulated PC1/3 and PC2 expression and lowered the proinsulin to insulin ratio in a dose- and time-dependent manner. Moreover, the beneficial effects of liraglutide on PC1/3 and PC2 expression and proinsulin processing were dependent on the GLP-1 receptor-mediated cAMP/protein kinase A signaling pathway. The same mechanism was recapitulated in isolated mouse islets. In conclusion, liraglutide enhanced PC1/3- and PC2-dependent proinsulin processing in pancreatic β-cells through the activation of the GLP-1 receptor/cAMP/protein kinase A signaling pathway. Our study provides a new mechanism for improvement of pancreatic β-cell function by the GLP-1-based therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614
cAMP-GEFII is a direct target of cAMP in regulated exocytosis
Ozaki, N., Shibasaki, T., Kashima, Y., Miki, T., Takahashi, K., Ueno, H., Sunaga, Y., Yano, H., Matsuura, Y., Iwanaga, T., et al. (2000) · Nature Cell Biology · doi:10.1038/35041046 · Cited by 481 · cited 2×
“Epac2 can promote insulin secretion by enhancing endoplasmic reticulum Ca(2) release (51) and subsequent exocytosis of insulin-containing granules (23).”
BackgroundReaven, G. M., Chen, Y. D., Hollenbeck, C. B., Sheu, W. H., Ostrega, D., & Polonsky, K. S. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.1.8421101 · Cited by 214
Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213
Drucker, D. J., Dritselis, A., & Kirkpatrick, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3148 · Cited by 181
Disproportionately Elevated Proinsulin in Pima Indians with Noninsulin-Dependent Diabetes Mellitus*
SAAD, M. F., KAHN, S. E., NELSON, R. G., PETTITT, D. J., KNOWLER, W. C., SCHWARTZ, M. W., KOWALYK, S., BENNETT, P. H., & PORTE, D. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-5-1247 · Cited by 167 · cited 1×
“At present, disproportional hyperproinsulinemia has been found in the individuals of type 2 diabetes (25, 26), impaired glucose tolerance (27, 28), and even nondiabetic first-degree relatives of the families with those with type 2 diabetes (29).”
BackgroundGlucose-Raising Genetic Variants in MADD and ADCY5 Impair Conversion of Proinsulin to Insulin
Wagner, R., Dudziak, K., Herzberg-Schäfer, S. A., Machicao, F., Stefan, N., Staiger, H., Häring, H.-U., & Fritsche, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023639 · Cited by 50
Cited by
von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00019-x · Cited by 186
Zhu, T., Wu, X.-L., Zhang, W., & Xiao, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920195 · Cited by 106
“Furthermore, several recent studies determined that the bio-active and pharmacological effects of GLP-1 analogs and DPP-4 inhibitors mainly resulted from the activation of a PKA-dependent signaling pathway [20,22,23].”
BackgroundBao, Y., Jiang, L., Chen, H., Zou, J., Liu, Z., & Shi, Y. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430199 · Cited by 60
New therapeutic approaches for type 1 diabetes: Disease-modifying therapies
Nagy, G., Szekely, T. E., Somogyi, A., Herold, M., & Herold, Z. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i10.835 · Cited by 23
Deshmukh, A., Chang, K., Cuala, J., Hernandez Campos, M. J., Mahmood, S., Verma, R., Georgia, S., Loconte, V., & White, K. L. (2025) · Structure · doi:10.1016/j.str.2025.07.022 · Cited by 9
Metadata
- Authors
- Wang, L., Liu, Y., Yang, J., Zhao, H., Ke, J., Tian, Q., Zhang, L., Wen, J., Wei, R., & Hong, T.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2014-10-01
- Volume
- 155
- Issue
- 10
- Pages
- 3817-3828
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2150237271
- Cited by
- 28
- References
- 9
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 Analog Liraglutide Enhances Proinsulin Processing in Pancreatic β-Cells via a PKA-Dependent Pathway. https://app.cochat.ai/papers/10.1210/en.2014-1218
- The paper
- Wang, L., Liu, Y., Yang, J., Zhao, H., Ke, J., Tian, Q., Zhang, L., Wen, J., Wei, R., & Hong, T. (2014). GLP-1 Analog Liraglutide Enhances Proinsulin Processing in Pancreatic β-Cells via a PKA-Dependent Pathway. Endocrinology. https://doi.org/10.1210/en.2014-1218
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.